UOC
MRNS

UBS O'Connor’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

UBS O'Connor’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-13,850
Closed -$298K – 532
2016
Q1 		$298K Buy
13,850
+5,725
+70% +$121K 0.01% 386
2015
Q4 		$248K Buy
+8,125
New +$238K ﹤0.01% 379
2015
Q1 		– Sell
-12,425
Closed -$524K – 870
2014
Q4 		$524K Buy
+12,425
New +$360K 0.01% 408

Other funds holding MRNS

CPV
Canaan Partners VII Westport, Connecticut $32.3M AUM 154.97% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

UBS O'Connor's MRNS Position: Q2 2016 in Review

UBS O'Connor sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2016, closing a stake of 13,850 shares — an estimated $298K sold.

UBS O'Connor first reported a position in MRNS in Q4 2014 and held it in 3 quarters. The position peaked at $524K in Q4 2014. 28 funds tracked by Wall St. Rank hold MRNS as of Q2 2016.

  • UBS O'Connor reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2016 after selling out during the quarter.
  • UBS O'Connor sold 13,850 Marinus Pharmaceuticals, Inc shares in Q2 2016, an estimated $298K.
  • UBS O'Connor first reported a position in Marinus Pharmaceuticals, Inc in Q4 2014 and held it in 3 quarters.
  • UBS O'Connor's Marinus Pharmaceuticals, Inc position peaked at $524K in Q4 2014.
  • 28 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2016.

Based on UBS O'Connor's 13F filing for Q2 2016, filed 12 Aug 2016.